From a purely public health perspective, the negative consequences of the ongoing mass vaccination campaigns can be summarized as follows:

Instead of forcing the virus into endemicity, mass vaccination campaigns will force more infectious viral variants into adaptation to the viral environment (i.e., the host[ile] population’s immune defense). This is to say that these campaigns will eventually drive dominant propagation of super variants that are not only highly infectious but that also increasingly resist vaccine-induced neutralizing Abs and could even be more virulent

Erosion of innate immune defense in the non-vaccinated (due to high infectious pressure exerted by enhanced circulation of more infectious variants)

Erosion of naturally acquired immunity (due to increasing viral resistance to neutralizing S-specific Abs)

2) and 3) combined prevent herd immunity from being established

Given all of these detrimental consequences, the question arises as to how on earth will we protect the human population from Covid-19 disease when the vaccines themselves will no longer be able to do so?


The answer is simple: Via herd immunity!


But how on earth can we build HI after the vaccines will precisely have prevented herd immunity from being established (due to erosion of both, naturally acquired and innate immunity as a direct (4) or indirect (5) consequence of mass vaccination, respectively)?


So, this comes down to asking ourselves the question as to how the population can build HI if it will have to start from scratch and is now even facing viral variants that are far more infectious, and potentially even more virulent, than the virus which circulated at the outset of this pandemic.


Here comes the answer:

Early treatment of people showing first sign and symptoms will result in enhanced rates of recovery from disease and, therefore, raise the number of people who develop life-long protective immunity against the viral variant they got infected with as well as against a diversified spectrum of other, more infectious circulating variants. Enhanced recovery rates will, therefore, contribute to building HI. This particularly applies when a large percentage of the population becomes highly susceptible to Covid-19 disease. Starting multidrug treatment at an early enough stage of the disease may, however, become much more challenging when dealing with ADE.

Mass antiviral treatment with whatever drug that effectively reduces viral infectious pressure. This will prevent innate Abs in previously asymptomatically infected individuals from being suppressed by short-lived, S-specific Abs and thus, enable the healthy, unvaccinated part of the population to deal with all Sars-CoV-2 variants. Such mass antiviral campaigns may need to include pets and live-stock (6) and be combined lockdown rules for as long as titers of these short-lived Abs are measurable (i.e., 6-8 weeks). In addition, healthy unvaccinated individuals are likely to contribute to further reducing viral infectious pressure as has recently been observed in the UK shortly after it opened up its society and economy following a period of lockdown rules (7). The higher the fraction of the unvaccinated population, the more ‘more infectious’ immune escape variants face competition from circulating less infectious variants (8) and the more dominant circulation of more infectious variants can be attenuated.

As Sars-CoV-2 is notorious for causing high viral shedding in the upper respiratory tract at an early stage of infection and has a high proportion of transmission even in pre‐symptomatic and asymptomatic individuals (9), the above measures are unlikely to succeed in sufficiently reducing transmission among healthy individuals. Asymptomatic Sars-CoV-2 transmission may become problematic in that it could result in regular outbreaks, especially in areas with higher population density (e.g., in cities) or at times where people have close physical contact (e.g., when they live more indoors during winter or at mass gatherings). A durable control of the pandemic will, therefore, ultimately require an immune intervention that is able to prevent infection in all age groups that are naturally susceptible to Covid-19 disease (10) (those are likely to include some age groups < 65 years due to the high level of innate immune suppression exerted by highly infectious circulating variants). As long as such an immune intervention is not available, antiviral chemoprophylaxis may need to be repeated at regular intervals. However, antiviral chemoprophylaxis should not be considered a long-term strategy since overuse of any antiviral compound could potentially promote viral resistance to it. It will, therefore, be critical to closely monitor viral infection rates and restart antiviral chemoprophylaxis as soon as a new surge in cases is about to start.

News – Vegetable Growers News
Farmers who sell locally eligible for new USDA insurance policy

➖ @OffgridiIreland ➖

News – Vegetable Growers News
Small producers eligible for Pandemic Response and Safety Grant program

➖ @OffgridiIreland ➖

Reuters: Sweden pauses use of Moderna COVID vaccine for younger age groups.
https://www.reuters.com/business/healthcare-pharmaceuticals/sweden-pauses-use-moderna-covid-vaccine-cites-rare-side-effects-2021-10-06

Here is a fun game to play go to the Australian Dictionary of Biography.
In the search bar type in Freemason and start reading

These filthy people and their families CONTROL EVERYTHING YOU SEE, HEAR and READ ... and still do today generation to generation filthy familes.

https://adb.anu.edu.au/biographies/search/?scope=all&query=Freemason&x=0&y=0&rs=

Ireland: "The whites are going extinct here now, we're taking over" — listen to the laughter at the end. They think it's funny and they're finally cocky enough to admit it openly.

“What is up with these anti-vaxxers! We’d be living in a free society if only they had accepted this forced vaccination program”
This is the kind of satire we badly need

Turkey tail mushroom